Literature DB >> 33736830

A Personalized Approach to Chronic Kidney Disease and Cardiovascular Disease: JACC Review Topic of the Week.

Ashton C Lai1, Solomon W Bienstock1, Raman Sharma1, Karl Skorecki2, Frans Beerkens1, Rajeev Samtani1, Andrew Coyle1, Tonia Kim1, Usman Baber1, Anton Camaj1, David Power1, Valentin Fuster3, Martin E Goldman4.   

Abstract

Cardiovascular disease is the most common cause of death in patients with end-stage renal disease (ESRD). The initiation of dialysis for treatment of ESRD exacerbates chronic electrolyte and hemodynamic perturbations. Rapid large shifts in effective intravascular volume and electrolyte concentrations ultimately lead to subendocardial ischemia, increased left ventricular wall mass, and diastolic dysfunction, and can precipitate serious arrhythmias through a complex pathophysiological process. These factors, unique to advanced kidney disease and its treatment, increase the overall incidence of acute coronary syndrome and sudden cardiac death. To date, risk prediction models largely fail to incorporate the observed cardiovascular mortality in the CKD population; however, multimodality imaging may provide an additional prognostication and risk stratification. This comprehensive review discusses the cardiovascular risks associated with hemodialysis, and explores the pathophysiology and the novel utilization of multimodality imaging in CKD to promote a personalized approach for these patients with implications for future research.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; chronic kidney disease; hemodialysis

Year:  2021        PMID: 33736830     DOI: 10.1016/j.jacc.2021.01.028

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status.

Authors:  Josep Redon; Maria Jose Forner; Jose Miguel Calderon; Fernando Martinez; Antonio Fernandez; Inmaculada Sauri; Javier Diaz; Ruth Uso; Jose Luis Trillo
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

Review 2.  Antiplatelet Therapy in End-stage Renal Disease Patients on Maintenance Dialysis: a State-of-the-art Review.

Authors:  Pietro Igor Ponchia; Raheel Ahmed; Mohamed Farag; Mohammad Alkhalil
Journal:  Cardiovasc Drugs Ther       Date:  2022-07-22       Impact factor: 3.947

3.  Prediction and Risk Stratification of Cardiovascular Disease in Diabetic Kidney Disease Patients.

Authors:  Jingjing Ren; Dongwei Liu; Guangpu Li; Jiayu Duan; Jiancheng Dong; Zhangsuo Liu
Journal:  Front Cardiovasc Med       Date:  2022-06-24

4.  Clinical characteristics of COVID-19 patients with complications: implications for management.

Authors:  Fen Lan; Chen Zhu; Rui Jin; Lingxiao Zhou; Yue Hu; Jianping Zhao; Shuyun Xu; Yang Xia; Wen Li
Journal:  Ther Adv Chronic Dis       Date:  2021-09-11       Impact factor: 5.091

5.  IGF-1 and Cardiovascular and Non-Cardiovascular Mortality Risk in Patients with Chronic Kidney Disease: A Model of "Malnutrition-Inflammation-Atherosclerosis Syndrome".

Authors:  Michio Shimabukuro
Journal:  J Atheroscler Thromb       Date:  2022-04-13       Impact factor: 4.394

6.  The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23.

Authors:  José Alberto Navarro-García; Rafael Salguero-Bodes; Laura González-Lafuente; Laura Martín-Nunes; Elena Rodríguez-Sánchez; Teresa Bada-Bosch; Eduardo Hernández; Evangelina Mérida-Herrero; Manuel Praga; Jorge Solís; Fernando Arribas; Héctor Bueno; Makoto Kuro-O; María Fernández-Velasco; Luis Miguel Ruilope; Carmen Delgado; Gema Ruiz-Hurtado
Journal:  BMC Med       Date:  2022-01-19       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.